# Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc

> The FDA approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), sponsored by ARGENX SE (ARGX), on June 20, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) |
| Codes |  |
| Sponsor | ARGENX SE (ARGX) https://sec-api.dev/companies/argx/catalysts |
| Indications |  |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### June 20, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761304 ORIG-1: submission_status AP, submission_status_date 20230620, review_priority PRIORITY; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22

### June 21, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761304 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20240621, review_priority PRIORITY; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22

### August 8, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761304 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20240808, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22

### April 10, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761304 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20250410, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22

### October 17, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761304 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22

### May 8, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761304 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260508, review_priority PRIORITY; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc

```bibtex
@misc{secapidev_pdufa_efgartigimod_alfa_and_hyaluronidase_qvfc_20261116,
  title        = {Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_efgartigimod_alfa_and_hyaluronidase_qvfc_20261116","title":"Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
